LangAware key facts
as of Oct 2026- Developer of diagnosis technology designed to be used for the early detection of various neurodegenerative diseases.
- LangAware is valued at approximately $12.1M as of Oct 2026 (last reported valuation).
- It has raised $4.6M; the latest was Later Stage VC ($320K) in Mar 2025.
- Notable investors include Endeavor Greece, Eleven Ventures, Cleverage Venture Capital, Georgios Georgios, Metavallon VC — 6 tracked in total.
- Status: Privately Held (backing).
LangAware's last reported valuation, Oct 2023. Nothing priced has surfaced since.
- ·Watch LangAware: the Monday email on marks, rounds and moves
LangAware funding rounds
No funding rounds for LangAware are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
LangAware valuation
LangAware's last reported valuation was $12.1 million in Oct 2023. No priced round, secondary trade or fund mark has surfaced since.
LangAware investors
6 investors are on record for LangAware, including Endeavor Greece, Eleven Ventures, Cleverage Venture Capital and Georgios Georgios.
About LangAware
Developer of diagnosis technology designed to be used for the early detection of various neurodegenerative diseases. The company's technology uses artificial intelligence and machine learning to predict neurodegenerative diseases by detecting and monitoring digital biomarkers based on language and speech, enabling physicians and patients to have an early cognitive assessment to prevent Alzheimer's and related dementias.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2019
- Employees
- 11
- Website
- langaware.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.